Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

8月3日， 沃森生物 公告显示，公司与复旦大学、上海蓝鹊生物联合研发的RSV mRNA疫苗，已正式获国家药监局临床试验申请受理。这款基于自主研发mRNA技术平台的疫苗，瞄准的是预防RSV感染引起的下呼吸道相关疾病—— ...

The CDC expanded RSV vaccine recommendations to include adults aged 50 and above who have underlying health conditions ...